The Oxidative Modification of Von Willebrand Factor Is Associated with Thrombotic Angiopathies in Diabetes Mellitus

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Oggianu, Laura ^a,b   Lancellotti, Stefano ^a   Pitocco, Dario ^a   Zaccardi, Francesco ^a   Rizzo, Paola ^a   Martini, Francesca ^a   Ghirlanda, Giovanni ^a   de Cristofaro, Raimondo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AGAROSE; CARBONYL DERIVATIVE; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLASMA PROTEIN; POLYMER; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA BASE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GEL ELECTROPHORESIS; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SDS AGAROSE GEL ELECTROPHORESIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADAM PROTEINS; ADULT; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOASSAY; ITALY; MIDDLE AGED; OXIDATION-REDUCTION; PROTEIN CARBONYLATION; STATISTICS, NONPARAMETRIC; THROMBOTIC MICROANGIOPATHIES; TRIGLYCERIDES; VON WILLEBRAND FACTOR;

EID: 84873182274     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055396     Document Type: Article

References (49)

1. Brownlee M, (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625.
2. Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, et al. (2007) Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 115: 2178-2187.
3. Leopold JA, Loscalzo J, (2009) Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med 47: 1673-1706.
4. Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, et al. (2008) Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem 283: 33846-33853.
5. Lancellotti S, De Filippis V, Pozzi N, Peyvandi F, Palla R, et al. (2010) Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med 48: 446-456.
6. De Filippis V, Lancellotti S, Maset F, Spolaore B, Pozzi N, et al. (2012) Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. Biochem J 442: 423-432.
7. Chen J, Fu X, Wang Y, Ling M, McMullen B, et al. (2011) Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood 115: 706-712.
8. Giacco F, Brownlee M, (2010) Oxidative stress and diabetic complications. Circ Res 107: 1058-1070.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462-1536.
10. Kemperman FA, Krediet RT, Arisz L, (2002) Formula-derived prediction of the glomerular filtration rate from plasma creatinine concentration. Nephron 91: 547-558.
11. Stephenson JM, Fuller JH, Viberti GC, Sjolie AK, Navalesi R, (1995) Blood pressure, retinopathy and urinary albumin excretion in IDDM: the EURODIAB IDDM Complications Study. Diabetologia 38: 599-603.
12. van Schooten CJ, Denis CV, Lisman T, Eikenboom JC, Leebeek FW, et al. (2007) Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood 109: 2430-2437.
13. Stadtman ER, Levine RL, (2000) Protein oxidation. Ann N Y Acad Sci 899: 191-208.
14. Udvardy ML, Szekeres-Csiki K, Harsfalvi J, (2009) Novel evaluation method for densitometric curves of von Willebrand factor multimers and a new parameter (M(MW)) to describe the degree of multimersation. Thromb Haemost 102: 412-417.
15. De Cristofaro R, Peyvandi F, Palla R, Lavoretano S, Lombardi R, et al. (2005) Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13. J Biol Chem 280: 23295-23302.
16. Katz M (2011) Multivariable Analysis. A Practical Guide for Clinicians and Public Health Researchers. Cambridge, UK: Cambridge University Press. 89 p.
17. Sinclair AJ, Taylor PB, Lunec J, Girling AJ, Barnett AH, (1994) Low plasma ascorbate levels in patients with type 2 diabetes mellitus consuming adequate dietary vitamin C. Diabet Med. 11: 893-898.
18. Gandhi CR, Roy Chowdhury D, (1979) Effect of diabetes mellitus on sialic acid & glutathione content of human erythrocytes of different ages. Indian J Exp Biol 17: 585-587.
19. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP, (2011) Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 34Suppl 2: S285-290.
20. Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R, (1995) Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 18: 87-89.
21. Seligman BG, Biolo A, Polanczyk CA, Gross JL, Clausell N, (2000) Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care 23: 1395-1400.
22. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, et al. (1996) Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39: 1540-1545.
23. Adeniyi A, Folsom AR, Brancati FL, Desvorieux M, Pankow JS, et al. (2002) Incidence and risk factors for cardiovascular disease in African Americans with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. J Natl Med Assoc 94: 1025-1035.
24. Hajer GR, van Haeften TW, Visseren FL, (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 29: 2959-2971.
25. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF, (2004) Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104: 100-106.
26. Skeppholm M, Kallner A, Kalani M, Jorneskog G, Blomback M, et al. (2009) ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus. Blood Coagul Fibrinolysis 20: 619-626.
27. Taniguchi S, Hashiguchi T, Ono T, Takenouchi K, Nakayama K, et al. (2010) Association between reduced ADAMTS13 and diabetic nephropathy. Thromb Res 125: e310-316.
28. George JN, (2006) Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 354: 1927-1935.
29. Suzukawa K, Miura K, Mitsushita J, Resau J, Hirose K, et al. (2000) Nerve growth factor-induced neuronal differentiation requires generation of Rac1-regulated reactive oxygen species. J Biol Chem 275: 13175-13178.
30. Vepa S, Scribner WM, Parinandi NL, English D, Garcia JG, et al. (1999) Hydrogen peroxide stimulates tyrosine phosphorylation of focal adhesion kinase in vascular endothelial cells. Am J Physiol 277: L150-158.
31. Pozzi N, Lancellotti S, De Cristofaro R, De Filippis V, (2012) Modeling ADAMTS13-von Willebrand factor interaction: Implications for oxidative stress-related cardiovascular diseases and type 2A von Willebrand disease. Biophys Chem 160: 1-11.
32. Fu X, Chen J, Gallagher R, Zheng Y, Chung DW, et al. (2011) Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. Blood 118: 5283-5291.
33. Di Stasio E, De Cristofaro R, (2010) The effect of shear stress on protein conformation: Physical forces operating on biochemical systems: The case of von Willebrand factor. Biophys Chem 153: 1-8.
34. van Schie MC, Wieberdink RG, Koudstaal PJ, Hofman A, Ikram MA, et al. (2012) Genetic Determinants of Von Willebrand Factor Plasma Levels and the Risk of Stroke: The Rotterdam Study. J Thromb Haemost 10: 550-556.
35. Frankel DS, Meigs JB, Massaro JM, Wilson PW, O'Donnell CJ, et al. (2008) Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation 118: 2533-2539.
36. De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C, (2012) Von Willebrand factor: an emerging target in stroke therapy. Stroke 43: 599-606.
37. Ferreiro JL, Angiolillo DJ, (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123: 798-813.
38. Vera RH, Vilahur G, Ferrer-Lorente R, Pena E, Badimon L, (2012) Platelets Derived From the Bone Marrow of Diabetic Animals Show Dysregulated Endoplasmic Reticulum Stress Proteins That Contribute to Increased Thrombosis. Arterioscler Thromb Vasc Biol 32: 2141-2148.
39. Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, et al. (2011) Endothelial von Willebrand factor regulates angiogenesis. Blood 117: 1071-1080.
40. Petri B, Broermann A, Li H, Khandoga AG, Zarbock A, et al. (2010) von Willebrand factor promotes leukocyte extravasation. Blood 116: 4712-4719.
41. Nicolucci A, De Berardis G, Sacco M, Tognoni G, (2007) AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 28: 1925-1927.
42. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, et al. (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352: 1293-1304.
43. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, et al. (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Jama 300: 2134-2141.
44. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, et al. (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337: a1840.
45. Hawiger J, (1991) Adhesive interactions of platelets and their blockade. Ann N Y Acad Sci 614: 270-278.
46. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, et al. (2007) First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116: 2678-2686.
47. Ulrichts H, Silence K, (2011) Schoolmeester A, de Jaegere P, Rossenu S, et al (2011) Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 118: 757-765.
48. Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, et al. (2011) The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke 42: 2149-2153.
49. Navarrete AM, Casari C, Legendre P, Marx I, Hu JR, et al. (2012) A murine model to characterize the anti thrombotic effect of molecules targeting human von Willebrand factor. Blood 120: 2723-2732.